Journal article
Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, F Janku, A Dasari, W Chung, JPJ Issa, P Gibbs, B James, G Powis, KB Nolop, S Bhattacharya, L Saltz
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
Purpose: BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with BRAF V600E-positive metastatic CRC was unknown. Patients and Methods: In this multi-institutional, open-label study, patients with metastatic CRC with BRAF V600 mutations were recruited to an expansion cohort at the previously determined maximum-tolerated dose of 960 mg orally twice a day. Results: Twenty-one patients were enrolled, of whom 20 had received at least one prior metastatic chemotherapy regimen. Grade 3 tox..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by Plexxikon and Roche. The correlative work was supported in part by the National Institutes of Health Cancer Center Support Grant No. CA16670 to The University of Texas MD Anderson Cancer Center. The authors acknowledge support from the National Cancer Institute under Awards No. R01CA172670 (S.K., G.P.), R01 CA160398 (G.P.), and R01CA184843 (S.K.).